PATIENT ASSISTANCE PROGRAMS
The following is a partial list of programs to help people get the testing, medical care, and medications they need to treat and cure Hepatitis C if they do not have insurance coverage or financial resources to pay for the services and medications.
Patient Access Network (PAN) Foundation: is an independent non-profit organization that provides assistance to underinsured patients for their out of pocket medical expenses. PAN assistance covers multiple Hepatitis C medications and a patient's choice of medication does not influence the amount of assistance a patient is able to receive.
To qualify for PAN assistance:
1-Patient should be insured and insurance must cover the medication for which a patient seeks assistance.
2-The medication must treat the disease directly.
3-Patient must reside and receive treatment in the United States.
4-Patient's gross income must fall below 500% of the Federal Poverty Level.
To learn more or to apply, visit www.panfoundation.org or call 1866-316-7263
Patient Advocate Foundation
To provide Hepatitis C patients with hands-on case management support
Hepatitis C Co-Pay Relief fund award
HIV, AIDS and Prevention Co-Pay Relief fund
Learn more at www.patientadvocate.org
Hepatitis C CareLine-1800-532-5274
The following is a partial list of programs to help people get the testing, medical care, and medications they need to treat and cure Hepatitis C if they do not have insurance coverage or financial resources to pay for the services and medications.
Patient Access Network (PAN) Foundation: is an independent non-profit organization that provides assistance to underinsured patients for their out of pocket medical expenses. PAN assistance covers multiple Hepatitis C medications and a patient's choice of medication does not influence the amount of assistance a patient is able to receive.
To qualify for PAN assistance:
1-Patient should be insured and insurance must cover the medication for which a patient seeks assistance.
2-The medication must treat the disease directly.
3-Patient must reside and receive treatment in the United States.
4-Patient's gross income must fall below 500% of the Federal Poverty Level.
To learn more or to apply, visit www.panfoundation.org or call 1866-316-7263
Patient Advocate Foundation
To provide Hepatitis C patients with hands-on case management support
Hepatitis C Co-Pay Relief fund award
HIV, AIDS and Prevention Co-Pay Relief fund
Learn more at www.patientadvocate.org
Hepatitis C CareLine-1800-532-5274
Good Days
www.gooddaysfromcdf.org
Soft Transfer phone number: 855-215-2715
Monday - Friday 8 a.m. - 5 p.m. Central Standard Time
Good Days is a 501c3 charity providing financial assistance to patients who cannot afford the medications they need to battle their disease. Specifically, Good Days removes the barriers to patient access by helping cover the out-of-pocket costs for approved medication after insurance. This includes copayments, deductibles and coinsurance.
Financial Assistance Guidelines
www.gooddaysfromcdf.org
Soft Transfer phone number: 855-215-2715
Monday - Friday 8 a.m. - 5 p.m. Central Standard Time
Good Days is a 501c3 charity providing financial assistance to patients who cannot afford the medications they need to battle their disease. Specifically, Good Days removes the barriers to patient access by helping cover the out-of-pocket costs for approved medication after insurance. This includes copayments, deductibles and coinsurance.
Financial Assistance Guidelines
- Patient should be insured
- The medication must be FDA approved to specifically treat the disease directly
- Insurance must cover the qualifying medication for which patient seeks assistance.
- Patient must be a U.S. citizen with U.S. residency and receive treatment in the United States
- Patient’s income must fall at or below 500% of the Federal Poverty Level
HarborPath is a non-profit organization dedicated to helping the uninsured living with HIV/AIDS and/or Hepatitis C gain access to free medications offered by Patient Assistance Programs (PAPs) by creating a single place for application and medication fulfillment. This "one stop shop" portal provides a streamlined, online process to qualify individuals and deliver the donated medications of the participating pharmaceutical companies through a mail-order pharmacy.
www.harborpath.org/hepatitis-c-patient
www.harborpath.org/hepatitis-c-patient
HEPATITIS C TREATMENT MEDICATIONS
Most pharmaceutical companies offer help to patients who cannot afford the medications needed to treat Hepatitis C. You should work with your doctor to select and contact programs for assistance. In fact, your doctor may have the forms you need to submit to get medications at reduced cost or no cost. Your doctor may help you apply for assistance.
Some pharmaceutical companies also offer programs to help patients learn more about Hepatitis C and manage treatment side effects. Check those out too.
AbbVie -MAVYRET (Glecaprevir/Pibrentasvir) FDA Approved August 3rd 2017
For the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both
AbbVie Patient Assistance Program
www.mavyret.com
1877-6289-9738 CALL TO LEARN MORE
Gilead-Vosevi (Sofosbuvuir/Valpatasvir/Voxilaprevir) FDA Approved July 18th, 2017
Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A.
Epclusa (Sofosbuvuir/Valpatasvir) FDA Approved June 28th, 2016
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:
- without cirrhosis or with compensated cirrhosis
- with advanced cirrhosis (decompensated) in combination with ribavirin
EPCLUSA contains the two medicines: sofosbuvir and velpatasvir.
It is not known if EPCLUSA is safe and effective in children under 18 years of age.
Gilead Patient Assistance Program
www.mysupportpath.com
For the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both
AbbVie Patient Assistance Program
www.mavyret.com
1877-6289-9738 CALL TO LEARN MORE
Gilead-Vosevi (Sofosbuvuir/Valpatasvir/Voxilaprevir) FDA Approved July 18th, 2017
Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A.
Epclusa (Sofosbuvuir/Valpatasvir) FDA Approved June 28th, 2016
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:
- without cirrhosis or with compensated cirrhosis
- with advanced cirrhosis (decompensated) in combination with ribavirin
EPCLUSA contains the two medicines: sofosbuvir and velpatasvir.
It is not known if EPCLUSA is safe and effective in children under 18 years of age.
Gilead Patient Assistance Program
www.mysupportpath.com
Merck Patient Assistance Program
This private and confidential program provides medicine free of charge to eligible individuals, primarily the uninsured who, without our assistance, could not afford needed Merck medicines. Individuals who don’t meet the insurance criteria may still qualify for the Merck Patient Assistance Program if they attest that they have special circumstances of financial and medical hardship, and their income meets the program criteria. A single application may provide for up to 1 year of medicine free of charge to eligible individua-s and an individual may reapply as many times as needed.
|
|
Contact Information If you have any questions about the Merck Patient Assistance Program including the status of an application, please call 1-800-727-5400, 8 AM to 8 PM EST, Monday through Friday.
Abbvie - Vikiera Pak
AbbVie has launched a patient support program, called proCeed™, which is intended to provide a broad range of patient support options. The proCeed program can be accessed soon at www.viekira.com or by calling 1-844-2-PROCEED.
https://www.viekira.com/proceed-program Patient Support Program
Viekira Pak
1-844-2-PROCEED
www.viekira.com
AbbVie has launched a patient support program, called proCeed™, which is intended to provide a broad range of patient support options. The proCeed program can be accessed soon at www.viekira.com or by calling 1-844-2-PROCEED.
https://www.viekira.com/proceed-program Patient Support Program
Viekira Pak
1-844-2-PROCEED
www.viekira.com
Gilead
Sovaldi (Sofosbuvir)
Harvoni (Ledipasvir)
Gilead - Harvoni, Sovaldi
http://www.harvoni.com/
http://www.gilead.com/responsibility/us-patient-access/support path for sovaldi and harvoni
http://www.mysupportpath.com/
https://www.harvoni.com/support
Sovaldi (Sofosbuvir)
Harvoni (Ledipasvir)
- Call center staffed with associates trained to help patients and their providers with insurance-related needs.
- U.S. Patient Support Program
- Gilead is committed to ensuring that people with hepatitis C can access Sovaldi and has launched Support Path(tm) (www.MySupportPath.com) to provide assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program consists of an integrated offering of support services for patients and providers, including:
- To assist eligible hepatitis C patients in the United States with access to Harvoni, Gilead has added the medicine to its Support Path™ (www.MySupportPath.com) program. The program consists of an integrated offering of support services for patients and providers, among them:
- Education and support, including a 24/7 nursing support service line.
- The Harvoni and Sovaldi Co-pay Coupon Programs, which provide co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs. Most patients will pay no more than $5 per co-pay.
Gilead - Harvoni, Sovaldi
http://www.harvoni.com/
http://www.gilead.com/responsibility/us-patient-access/support path for sovaldi and harvoni
http://www.mysupportpath.com/
https://www.harvoni.com/support
Bristol-Myers Squibb’s Patient Support Connect Program
Bristol-Myers Squibb is committed to helping patients through treatment with Daklinza. For patient support and financial assistance, patients and physicians may call (844) 44-CONNECT (844-442-6663). This number offers one-stop access to a range of support services for patients and healthcare professionals alike, including benefits investigation by care counselors, comprehensive coverage research and emergency shipment for access-related issues.
Janssen
Olysio (Simeprevir)
Janssen - Simeprevir/Olysio
http://www.olysio.com/hcp/experience
Bristol-Myers Squibb is committed to helping patients through treatment with Daklinza. For patient support and financial assistance, patients and physicians may call (844) 44-CONNECT (844-442-6663). This number offers one-stop access to a range of support services for patients and healthcare professionals alike, including benefits investigation by care counselors, comprehensive coverage research and emergency shipment for access-related issues.
Janssen
Olysio (Simeprevir)
- Patients who lack adequate financial resources and do not have prescription coverage can apply to the Johnson & Johnson Patient Assistance Foundation, Inc., to determine if they meet eligibility criteria for financial assistance for OLYSIO:
- Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, private, nonprofit organization that assists patients who do not have financial resources or prescription drug coverage to obtain free prescription products that are donated by Johnson & Johnson operating companies. Janssen Therapeutics donates medicines, including OLYSIO, to JJPAF
- For additional information, please visit the JJPAF Web site at www.jjpaf.org or call and speak to one of our patient assistance program specialists at 1-800-652-6227
- Patients with prescription drug coverage that may require significant out-of-pocket (co-pay or co-insurance) expenses for OLYSIO may apply for assistance through OLYSIO Support:
- Patients who qualify for the OLYSIO patient savings program will pay no more than $25 per month for a total of $75 for three months out-of-pocket costs. This program is available to cover co-pays and co-insurance costs. Additional important information about the OLYSIO patient savings program:
- Subject to a $25,000 annual maximum, 12 months after activation, or 3 fills (12-week supply), whichever comes first
- Not valid for patients enrolled in Medicare (e.g., Medicare Part D) or Medicaid
- Information on the OLYSIO patient savings program and other access support services can be found at www.olysio.com or by calling 1-855-5-OLYSIO
- A 24/7 Nurse Support hotline
· A support group finder to help individuals connect with other people in their area who are seeking support on their hepatitis C journey
· A variety of resources to help individuals keep track of their treatment inclusive of a mobile app, dosing diary, treatment calendar,and reminder calls.
Janssen - Simeprevir/Olysio
http://www.olysio.com/hcp/experience
